Cirrhosis of the liver is most commonly divided into two broad clinical stages: compensated and decompensated. But depending on which classification system you’re looking at, you’ll see cirrhosis described in two, three, or four stages. The answer depends on whether doctors are talking about liver scarring overall, the severity of cirrhosis specifically, or your risk of complications.
The Two Main Clinical Stages
The most widely used distinction in everyday medicine splits cirrhosis into compensated and decompensated. In compensated cirrhosis, the liver is scarred but still functional enough to handle most of its jobs. You may have no symptoms at all during this stage, and many people don’t know they have cirrhosis until it’s found incidentally. Life expectancy with early compensated cirrhosis can still be upward of 15 years.
Decompensated cirrhosis means the liver can no longer keep up. This is when serious complications appear: fluid buildup in the abdomen (ascites), yellowing of the skin and eyes (jaundice), internal bleeding from swollen veins in the esophagus, or episodes of confusion and drowsiness caused by toxins the liver can no longer filter. Average life expectancy drops to about seven years once decompensation occurs, though individual outcomes vary widely based on the cause and whether treatment is available.
The Four-Stage Model of Liver Scarring
Before cirrhosis even enters the picture, doctors track liver damage on a scale from no scarring to full cirrhosis. The most common version of this scale, used especially in hepatitis-related liver disease, has four stages of fibrosis:
- F1: Mild scarring, limited to the area around the portal tracts (the liver’s internal “highways” for blood and bile).
- F2: Significant fibrosis that has started to extend beyond those portal areas.
- F3: Advanced fibrosis where bands of scar tissue bridge across the liver’s internal structure.
- F4: Cirrhosis. The scarring is widespread and has fundamentally changed the liver’s architecture.
In this system, cirrhosis is actually the final stage (F4), not a multi-stage disease on its own. So when someone asks “how many stages of cirrhosis,” part of the confusion comes from mixing up stages of liver scarring with stages within cirrhosis itself. Everything before F4 is fibrosis, not cirrhosis.
Child-Pugh Classes: A, B, and C
Once someone has cirrhosis, doctors use the Child-Turcotte-Pugh (CTP) scoring system to classify how severe it is. This system assigns points based on five factors: whether you have fluid buildup in the abdomen, whether you’re experiencing confusion from liver-related brain effects, and three blood test results that reflect how well the liver is producing proteins and processing waste.
The total points place you into one of three classes:
- Class A (5 to 6 points): Well-compensated cirrhosis. Liver function is still relatively preserved.
- Class B (7 to 9 points): Significant functional compromise. Symptoms and complications are more likely.
- Class C (10 to 15 points): Decompensated cirrhosis. The liver is severely impaired, and transplant evaluation is typically part of the conversation.
This is the system that most closely answers the question “how many stages” for someone already diagnosed with cirrhosis. It gives three distinct severity levels, each with different treatment approaches and outlooks.
The MELD Score and Transplant Priority
The other major scoring tool is the MELD score, which doesn’t group people into stages at all. Instead, it produces a number on a continuous scale that predicts the risk of dying within 90 days without a transplant. Hospitals use this number to determine where you fall on the transplant waiting list. A higher MELD score means greater urgency.
The most recent version, called MELD 3.0, factors in kidney function, blood clotting ability, bilirubin levels, blood albumin levels, sodium, and the patient’s sex. Earlier versions of the formula had a documented disparity that disadvantaged women on the transplant list. The updated model was specifically designed to correct that gap.
How Cirrhosis Is Detected Without a Biopsy
A liver biopsy, where a small sample of tissue is examined under a microscope, has long been the gold standard for confirming cirrhosis and its severity. But it’s invasive, and results can vary depending on where the sample is taken. One study found that nearly 10% of the time, a biopsy from one lobe of the liver would show advanced scarring while a biopsy from the other lobe showed minimal damage.
A non-invasive alternative called transient elastography (often known by the brand name FibroScan) measures liver stiffness using sound waves. A reading above 14 kilopascals (kPa) indicates roughly a 90% probability of cirrhosis. Readings above 7 kPa suggest at least significant fibrosis. This test takes only a few minutes and has become a standard part of screening for people with chronic liver disease.
How Symptoms Change as Cirrhosis Progresses
Cirrhosis often shows no symptoms until the damage is extensive. When early signs do appear, they tend to be vague: fatigue, weakness, unexplained weight loss, easy bruising, itchy skin, and small spider-like blood vessels visible on the skin. Redness on the palms of the hands is another early sign that’s easy to overlook.
Later-stage symptoms are more dramatic and harder to miss. Jaundice turns the skin and eyes yellow. The abdomen swells with fluid. Bleeding from the gastrointestinal tract can occur when pressure builds in the veins around the liver, a condition called portal hypertension. When portal hypertension develops, it significantly shortens life expectancy because of the risk of sudden, serious internal bleeding.
Sexual health is also commonly affected, though it’s rarely discussed. Men with cirrhosis frequently experience erectile dysfunction, reduced sex drive, and breast tissue enlargement. Women may lose their periods, have difficulty reaching orgasm, or stop ovulating entirely.
Can Cirrhosis Be Reversed?
For years, cirrhosis was considered a one-way street. That view has shifted. There is now clinical evidence that liver fibrosis, and even early cirrhosis, can partially regress when the underlying cause is removed or treated. In one study of 113 patients treated for various liver diseases (including hepatitis B, hepatitis C, and autoimmune liver disease), about 12% showed post-treatment regression from cirrhosis to significantly less scarring on repeat biopsy.
That said, the evidence comes with caveats. Because biopsy results can vary depending on where the sample is taken, some apparent “regression” could reflect sampling error rather than true reversal. And advanced decompensated cirrhosis with extensive structural changes is far less likely to reverse meaningfully. The window for potential improvement is widest when cirrhosis is caught early and the cause, whether it’s alcohol, a virus, or an autoimmune condition, is addressed aggressively.